[Considerations in the combination of clozapine and benzodiazepines].
Serious adverse events and even sudden death have been reported during administration of the combination of clozapine and benzodiazepines. However, this combination does not necessarily result in increased frequency of serious adverse events. Thus it is not regarded as an absolute contraindication and might be useful in distinct clinical situations, e.g., during the occurrence of a malignant neuroleptic syndrome, "catatonic dilemma," or severe agitation during clozapine treatment. In the following report, certain suggestions on how to deal with this combination therapy are provided which may provide a basis for discussion that ultimately may lead to the formulation of guidelines for this combination therapy. Such guidelines may help psychiatrists in dealing with this combination in clinical situations. Moreover, the formulation of such guidelines would help with forensic issues in case of serious adverse events occurring during this combination therapy.
Rupprecht
R
R
Klinik für Psychiatrie und Psychotherapie der Ludwig-Maximilians-Universität München, München, Deutschland. Rainer.Rupprecht@psy.med.uni-muenchen.de
Soyka
M
M
Grohmann
R
R
Rüther
E
E
Möller
H-J
HJ
D016907:Adverse Drug Reaction Reporting Systems; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000633:toxicity*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000633:toxicity*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000633:toxicity*; D002389:Catatonia / Q000139:chemically induced / Q000517:prevention & control; D003024:Clozapine / Q000008:administration & dosage / Q000633:toxicity*; D003645:Death, Sudden / Q000209:etiology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D012307:Risk Factors
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine